Home › Companies › IMMX

Immix Biopharma, Inc.

IMMX Rare disease Lead: Phase 2 2 Biotech Distilled articles ↓

Hematology Cell

Most recent annual filing: 2026-03-25

Pipeline (1 active programs)

NXC-201

Cell Target: BCMA

Relapsed/Refractory AL Amyloidosis Phase 2 Memorial Sloan Kettering Cancer Center

Technology platforms

N-GENIUS · Hadasit

Cell engineering platform with EXPAND technology and COBRA binder scaffold generation; produces CAR-T candidates targeting BCMA and other targets for hematologic, neurologic, rheumatologic, vascular and other serious diseases

Targets: BCMA

Biotech Distilled coverage (2)

2026-05-21 UPDATE: Immix Biopharma (IMMX) — The 95% CR Lands, and the Dilution Gap Closes Before It Opens 🔒 Paid
2026-05-12 Immix Biopharma (IMMX) - Scientific Deep Dive for NXC-201 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.